StockWatch
·
Pharmaceuticals
Corporate Governance11 Nov 2026, 05:50 pm

Godavari Drugs: Statement of Deviation/Variation for Q2 FY27

AI Summary

Godavari Drugs Ltd has submitted its Statement of Deviation or Variation for the quarter ended September 30, 2026, as per SEBI regulations. The company confirms that there has been no deviation or variation in the utilization of funds raised through a preferential issue, aligning with the stated objects. This statement was reviewed by the Audit Committee and approved by the Board of Directors on November 11, 2026.

Key Highlights

  • Statement of Deviation/Variation submitted for Q2 FY27.
  • No deviation in utilization of preferential issue funds.
  • Statement reviewed by Audit Committee and Board.
  • Confirmation aligns with EGM explanatory statement.